The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN

Aberrant JAK2 tyrosine kinase signaling drives the development of Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. However, JAK2 kinase inhibitors have failed to significantly reduce allele burden...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Adv
Egile Nagusiak: Mazzacurati, Lucia, Collins, Robert J., Pandey, Garima, Lambert-Showers, Que T., Amin, Narmin E., Zhang, Ling, Stubbs, Matthew C., Epling-Burnette, Pearlie K., Koblish, Holly K., Reuther, Gary W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2019
Gaiak:
Myeloid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6880903/
https://ncbi.nlm.nih.gov/pubmed/31725895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000260
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak